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Prostate cancer (PCa) field effect alterations provide
important clues regarding the initiation of these tu-
mors and suggest targets for prevention or biomark-
ers for early detection. However, biomarkers of PCa
field effects that have passed independent validation
are lacking, largely because these alterations are sub-
tle and difficult to distinguish from unrelated small
changes in gene expression. We hypothesized that
shared expression alterations in PCa and benign
prostates containing PCa (BPCs) would have a higher
potential for independent validation than alterations
identified in BPCs alone. Expression analyses were
performed on 37 PCas and 36 unmatched BPCs and
were contrasted with 28 benign prostates (BPs) from
patients free of PCa. Most of the protein-coding genes
and nonexonic RNAs selected according to the hy-
pothesis were validated by quantitative RT-PCR in an
independent set of 51 BPCs and BPs. A statistical
model based on twomarkers distinguished BPCs from
BPs in the RT-PCR set and in an external microarray
(area under the curve  0.84 and 0.90, respectively).
In addition, genes with predominant expression in
stroma were identified by expression profiling of
pure stroma and epithelial cells. Pathway analysis
identified dysregulated platelet-derived growth factor
receptor signaling in BPC stroma. These results vali-
date our approach for finding PCa field effect altera-
tions and demonstrate a PCa transcriptome finger-
print in nonneoplastic cells in prostates containing
cancer. (Am J Pathol 2012, 181:34–42; http://dx.doi.org/
10.1016/j.ajpath.2012.03.043)
34The diagnosis of prostate cancer (PCa) is based mainly
on needle biopsy of the prostate gland. However, needle
biopsy has a 30% false-negative rate due to sampling
error.1,2 As a result, many of the approximately 800,000
men with a negative biopsy result in the United States
each year undergo repeated biopsies, which can be
frustrating for patients and urologists. For benign prostate
needle biopsy specimens that lack atypical small acini or
high-grade prostatic intraepithelial neoplasia, there is no
additional information that can be gained by pathologic
assessment. However, the possibility that these prostate
glands harbor PCa is significant. Despite a lack of mor-
phologic changes, there is a considerable body of evi-
dence suggesting that molecular alterations associated
with tumor in adjacent nonneoplastic cells, the so-called
tumor field effect, can provide valuable clues regarding
the presence of tumor. The prostatic tumor field effect was
first reported 15 years ago based on subtle histologic
changes in the tissue architecture and cytologic features in
benign tissue adjacent to and at some distance from PCa.3
Subsequent studies have documented tumor-associated
molecular alterations in nonneoplastic tissue adjacent to
PCa in resected specimens and, notably, in needle bi-
opsy specimens.4,5 Recently, several investigators have
used microarrays to identify expression alterations asso-
ciated with PCa field effects.6–9 These profiles were often
independent of PCa and included limited or no indepen-
dent validation.
In this study, we sought to identify field effect altera-
tions that were shared in benign prostates from patients
with PCa (BPCs) and unmatched PCa. We posited that
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better possibility of independent validation than changes
identified in BPCs alone. In addition, gene expression
changes specific to benign prostate tissues, such as
changes related to hyperplasia, atrophy, postatrophic
hyperplasia, etc, would be excluded. Although the defi-
nition of field effect varies among investigators, we de-
fined the presence of alterations in the entire peripheral
zone of the prostate gland as field effect instead of
changes restricted to benign glands just adjacent to can-
cer. In addition, this study focused on high-grade PCa
(Gleason score 7), as these tumors are much more
likely to be clinically significant and more detrimental to
the patient if missed on the needle biopsy specimen.
Significant gene expression alterations in BPCs com-
pared with in benign prostate glands from patients free of
PCa who had their prostates resected during cystopros-
tatectomy for bladder cancer (BPs) were identified and
validated. These expression alterations are referred to as
markers in this article, and they refer to genes, pseudo-
genes, and transcribed non-exonic sequences. A logistic
regression model was developed and tested in two inde-
pendent data sets to determine the presence of PCa
based on field effect alterations in BPCs. We also studied
dysregulated pathways in BPC stroma by gene set en-
richment analysis. The results of this study indicate the
presence of a wide field effect in PCa and have important
implications in developing assays aimed at improving the
diagnosis and management of patients at risk for PCa.
Materials and Methods
Patient Samples
BP samples were from cystoprostatectomy procedures
performed at Mayo Clinic (Rochester, MN) between Jan-
uary 1, 2007, and December 31, 2011, on patients with
bladder cancer. Patients identified with incidental PCa in
their surgical records were excluded. BPC and PCa sam-
ples were obtained from the Mayo Clinic Specialized
Program of Research Excellence in Prostate Cancer tu-
mor bank. All patients with PCa and BPCs underwent
radical prostatectomy, and none had received preoper-
ative hormone therapy, chemotherapy, or radiotherapy.
PCa samples were from patients with a tumor Gleason
score 7 and were independent of BPC samples. The
discovery step by microarray expression profiling in-
cluded BPs (n  28), BPCs (n  36), and PCa (n  37).
In the BPC group, there were 16 samples from patients
with a Gleason score of 6 and 20 samples from patients
with a Gleason score 8. Quantitative RT-PCR (RT-
qPCR) experiments included BPs (n  15) and BPCs
(n 23) of the discovery samples for confirmation and an
independent set of BPs (n  18) and BPCs (n  33) for
validation. The BPC validation set included 15 samples
from patients with a Gleason score of 6 and 18 samples
from patients with a Gleason score 8. Finally, 16 inde-
pendent benign prostates from radical prostatectomy
and cystoprostatectomy operations were used in the la-ser capture microdissection (LCM) expression profiling to
identify stroma-related genes in pathway analysis.
Collection and Processing of Bulk Samples
Prostate tissue specimens were surgically excised and
submitted for surgical pathology analysis. All the speci-
mens were evaluated rapidly after removal from the pa-
tient. In each case, most of the peripheral zone was
examined by rapid frozen section, and after diagnostic
material was obtained, sections were collected for re-
search. Fresh cancer and benign tissue specimens (both
up to 2 cm in greatest dimension) were flash frozen in
liquid nitrogen. In cases of PCa, the benign prostatic
tissue was obtained from the peripheral zone on the
opposite side. At the time of collection, the distance from
main tumor mass to benign ranged from 0.5 to 2 cm.
Collection of BP samples included the peripheral zone of
prostates only. For all the samples, an H&E-stained sec-
tion was prepared from the snap-frozen tissue to ensure
that the tissue was appropriately identified and of ade-
quate quality. A careful pathologic examination excluded
cystoprostatectomy cases with lesions suspicious of in-
cidental prostate or bladder cancers on the tissue slides.
In cases where incidental microscopic foci of cancer
were present in BPCs, these foci were cut out of the
frozen tissue block by manual macrodissection. Similarly,
PCa samples were enriched for the tumor content by
macrodissecting nonneoplastic tissues. Samples with
significant inflammation and high-grade prostatic intra-
epithelial neoplasia were excluded. Frozen tissues were
sectioned and collected in a cryostat and kept frozen
(80°C) until RNA isolation. H&E-stained slides from be-
fore and after every 10 sections and at the end of sec-
tioning were inspected to ensure that no tumor cells con-
taminated BP and BPC samples.
RNA Isolation and Microarray Expression
Profiling of Bulk Samples
Total RNA from each sample was isolated using standard
kits (Qiagen Inc., Valencia, CA). DNase treatment was
performed on the RNA purification column to remove
genomic DNA contamination (RNase-free DNase set;
Qiagen Inc.). RNA quantity and quality were measured
by spectrophotometry and by Agilent 2100 bioanalyzer
(Agilent Technologies Inc., Santa Clara, CA). There was
no difference in the RNA quality assessed by the RNA
integrity number between the BP and BPC samples (see
Supplemental Figure S1 at http://ajp.amjpathol.org).
Labeling and hybridization to the Affymetrix U133Plus2
chips (Affymetrix Corp., Santa Clara, CA) followed stan-
dard protocols and used 1.0 to 1.2 g of total RNA.
Bioinformatics and Statistical Analysis
The microarray signal intensity (.cel) files from Mayo sam-
ples were normalized and processed by the gcrma pack-
age in R version 2.11.1 (http://cran.at.r-project.org). As an
additional measure of quality control for contamination of
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ETV1, ETV4, and SPINK1 were compared between BPCs
and BPs. Together, these four genes are overexpressed
in most prostate tumors. We did not see any evidence of
overexpression of these genes in any of the BPC samples
(data not shown).
Sammon Mapping
Clustering analysis used Sammon mapping in the
“MASS” library in R. Distance measures were calculated
by the “manhattan” method in the “stat” library.
Selection of Up-Regulated Genes
Two metrics used for gene selection were signal-to-
noise ratio (SNR) and P values by t-tests. SNRs were
calculated as SNR (1 2)/(1 2), where ’s were
mean expression values and ‘s were a maximum of
0.2   and SD.10 We also required that the average
expression in samples overexpressing a gene had 3.5
log2 intensity. Log2 expression intensities for the gcrma-
normalized data ranged from 1 to 16.5. Based on our
experience with RT-qPCR, gene expression intensities
3.5 were not reliable and often were not detected.
Seven genes with significant q values for multiple com-
parisons between BPCs and BPs (q  0.05) and AMACR
(q  0.06) based on the literature11,12 were selected for
validation by RT-PCR.
Permutation Analysis
The central objective of the analysis was to determine
whether the results obtained by using the BPC samples
could also be obtained by combining and randomly shuf-
fling the BP and BPC samples. We examined the overlap
between overexpressed genes compared with BPs in
BPCs and in PCa. In the list of 270 to 285 unique genes
Table 1. Primers Used in RT-qPCR Experiments
Probe set Marker Forward pri
Target genes
201291_s_at TOP2A 5=-AGATTCTGGACCAAC
204750_s_at DSC2 5=-CGCGATCTTAATATT
209631_s_at GPR37 5=-AACAAATAAATCTGA
204324_s_at GOLIM4 5=-TGTGATGTTGGAAAG
216867_s_at PDGFA 5=-TCGGGAGAACAAAGA
213668_s_at SOX4 5=-ACTTCGAGTTCCCGG
228729_at CCNB1 5=-AATGGTGAATGGACA
209426_s_at AMACR 5=-CACGTGAAACAGAGT
210469_at DLG5 5=-GAGAAGCCCGCACTT
222018_at NACA 5=-CCTTTGTTCCTTGAC
226848_at NR2C2 5=-CAGATGTGTTCCCTT
227751_at PDCD5 5=-GGGAGAAAGGCTGAA
1556026_at IDSP1 5=-GGTGGATTTGAGAAG
Normalization genes
47105_at DUS2L 5=-CCATCAGCCTAGAGC
201632_at EIF2B1 5=-GAATCTGCATCTGGC
52169_at STRADA 5=-GCGACCAGCCTCATT
210574_s_at NUDC 5=-AGATGATGTATGACC
213867_x_at ACTB 5=-TCCTCTCCCAAGTCCAmL, amplicon length.(350 probe sets) with the highest SNRs comparing BPCs
and PCa with BPs, there were 19 overlapping genes and
expressed sequence tags (21 probe sets) with significant
P values (P  0.05). To determine the likelihood of this
overlap, we assigned a randomly selected 28 of the BP
and BPC samples into one group (group 1) and the
remaining 36 into another group (group 2) and identified
the overlap in 350 probe sets with the highest SNRs and
significant (P  0.05) overexpression in group 2 and PCa
compared with group 1. This process was repeated 1000
times, and each time the number of overlapping probe
sets was recorded to generate a histogram.
Selection of Down-Regulated Genes
Probe sets (n  50) with the lowest SNRs that were
significant (P  0.05) in BPCs and PCa compared with
BPs were considered. These probe sets were also sig-
nificant in BPCs after multiple comparison correction
(q  105). Five probe sets corresponding to misspliced
or nonexonic RNA were selected for RT-PCR analysis.
Confirmation and Validation by RT-qPCR
Total RNA (125 to 500 ng) was used in reverse transcrip-
tion using SuperScript III (Invitrogen, Carlsbad, CA). Af-
fymetrix probe set target sequences were used to design
primers on the Primer3 website (http://frodo.wi.mit.edu/
primer3, last accessed February 1, 2011). All qPCRs were
performed in duplicates using a Dynamic Array inte-
grated fluidic circuit (Fluidigm Corp., San Francisco, CA).
Each primer set was tested by a 4-point standard curve.
Five genes, including ACTB, were used to normalize the
data. The other four normalizer genes (DUS2L, EIF2B1,
LYK5, and NUDC) were identified based on small stan-
dard deviations in the BP and BPC samples in
the microarray data. Table 1 includes the primer se-
quences. Reported values were calculated as referencex
Reverse primer AmL
AC-3= 5=-GCCTGCAGAGTTCATCTTTCTT-3= 83
GT-3= 5=-TTTCTCGGCATCTAGTTTGGAG-3= 76
CCAA-3= 5=-ATACGCCGTGAAATGTCCACT-3= 82
TG-3= 5=-AACAAAGAACACCTGGGAACTG-3= 81
TG-3= 5=-TACTGCTTCACCGAGTGCTACA-3= 77
TG-3= 5=-CAGGTTGGAGATGCTGGACTC-3= 83
TC-3= 5=-ATTCTTAGCCAGGTGCTGCATA-3= 87
GT-3= 5=-TGGAATGTGCTTAGAGGGAGAT-3= 75
AT-3= 5=-TGCAATCTGAACACCTGACTTG-3= 76
CT-3= 5=-TGGAATGAGGTTCCTTAATTGG-3= 91
TTG-3= 5=-CCTCTGTTGATGAATTTCCAGGT-3= 84
TG-3= 5=-AAAGGGTGGGAATGGAGTCA-3= 70
GA-3= 5=-ACACTACAGCATTCAGGGTTCC-3= 84
C-3= 5=-CCTGTCACTCAGATCCACCAA-3= 74
-3= 5=-CCTTCCTCGTGTTCTCTTGGTA-3= 87
TA-3= 5=-GGCAGCTTACTACTTGCCCTTT-3= 82
CA-3= 5=-AATCTCCTGTTTCTTCTGTTCGTC-3= 71
-3= 5=-GCACGAAGGCTCATCATTCA-3= 129mer
CTTCA
TGCCA
CCCAA
CTCAT
GACAG
ACTAC
CCAAC
GATTG
TCTAC
TCCCT
CACTC
TCTGT
ATGTG
ATGGA
TTCCA
CTATT
AGCGA
ACACA
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five housekeeping genes in sample x and markerg,x is the
raw expression for marker g in sample x.
Logistic Regression
RT-qPCR data on the confirmation and validation sets
were used to build and test a logistic regression model.
To minimize overfitting, model building was limited to two
markers. The first parameter to enter the model in the
confirmation set was NACA, followed by CCNB1. These
two markers produced the highest area under the curve
(AUC) in the validation set also. For additional testing,
we used the public data set of Wang et al13 (Gene Ex-
pression Omnibus record GSE17951). Expression data
were extracted from the signal intensity files (.cel files) by
the gcrma package in R. The model was first built in the
Mayo Clinic microarray data set, and the model coef-
ficients for the two markers were applied to the data set
of Wang et al13 (GSE17951). In this data set, benign
samples with 0% tumor from patients with PCa accord-
ing to the sample information file were categorized as
BPCs, and organ donor samples were categorized as
BPs. The study by Wang et al focused on the expression
profiles of prostate stroma adjacent to tumor. By inspect-
ing the prostate-specific antigen expression levels, we
identified seven samples in this data set with low epithe-
lial content (see Supplemental Figure S2 at http://ajp.am-
jpathol.org). The logistic regression model was tested
with and without these samples.
Expression Profiling of the Prostate Stroma and
Epithelia
LCM was used to collect 11 epithelial cell populations
from cystoprostatectomy operations and 5 stromal sam-
ples (4 matching epithelial collections and 1 from a rad-
ical prostatectomy operation). Close to 5000 LCM pulses
were used for each sample. Total RNA was isolated using
the PicoPure kit (Arcturus Corp., Mountain View, CA). The
quality and quantity of RNA from the LCM samples were
controlled by a qPCR assay based on the ratio of con-
centration of 3= to middle transcript of -actin. Details of
this procedure and for sectioning and processing of
slides, LCM, and linear amplification are described pre-
viously.14 Briefly, this protocol required 2 ng of starting
total RNA and used a slightly modified version of the
Affymetrix small sample preparation protocol (Affymetrix
Corp.). Biotin-labeled amplified cDNA samples were hy-
bridized to the U133Plus2 chips according to the stan-
dard Affymetrix protocols.
Pathway Analysis
We aimed to identify enriched gene ontology (GO) cate-
gories in BPC stroma. Genes differentially expressed in
BPC stroma compared with BP stroma were identified in
a two-step process. The first step selected probe sets
that were significantly up- or down-regulated in BPCs
compared with in BPs after adjusting for multiple com-parisons15 (q  0.05) in the bulk microarray data. The
second step selected probe sets with more prominent
expression in prostate stroma than in prostate epithelia
cells in the LCM data set. Probe sets that were signifi-
cantly higher in stroma (q  0.05) with a fold change 2
were selected. Steps 1 and 2 had 278 common probe
sets representing 218 unique genes.
Expression values of these probe sets in the bulk data
set were input to the Matisse software package (Matisse
Software Inc., Mountain View, CA) to identify enriched
GO categories. The DEGAS (Dysregulated Gene Set
Analysis via Subnetworks) algorithm was used to build a
network of genes dysregulated in BPCs.16 Other than the
gene expression data, DEGAS requires a protein inter-
action network. We used the 2007 human functional link-
age network (Human_Interactome_May.sif).17 Probe
sets/genes with twofold differential expression compared
with BPs in a subset of 31 or more BPCs were selected to
build a network (I  5 in DEGAS). Identified GO catego-
ries in the network were tested by the TANGO module in
the Matisse software package for statistical significance
after correcting for multiple comparisons.
Results
No Evidence of Systematic Differences in the
Expression Profiles of Benign Samples from
Patients with and without PCa
Significant disparities in ischemia time or tissue process-
ing between benign samples from patients with (BPCs)
and without (BPs) PCa can confound the influence of PCa
field effect on gene expression. Such disparities can be
readily detected by a clustering analysis, such as Sam-
mon mappings. We selected the most variable probe
sets in the expression profiles of BPCs and BPs. Sammon
mapping by these probe sets did not separate BPs from
BPCs (Figure 1A). The two groups were intermixed and
did not separate into discrete groups. Changing the num-
ber of selected probe sets did not alter the patterns. We
also examined whether there were major influences of
ischemia in differential gene expression profiles. Two
publications by Lin et al18 and Dash et al19 describe the
Figure 1. BPs and BPCs do not show expression differences due to dispar-
ities in tissue processing or ischemia. A: Sammon map of the most variable
probe sets (n  350) in BPs (green dots) and BPCs (red dots) does not
separate these two groups. B: Sammon map that uses the most variable probe
18sets corresponding to the ischemia-related genes by Lin et al does not
separate the BP and BPC samples.
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during and after prostate operations, respectively. A
Sammon map that used the most variable or all probe
sets corresponding to the significant genes by Lin et al
(Figure 2 in the referenced article) did not separate BPCs
from BPs (Figure 1B; also see Supplemental Figure S3A
at http://ajp.amjpathol.org). Similarly, probe sets corre-
sponding to the genes reported by Dash et al did not
separate the two groups (see Supplemental Figure S3, B
and C, at http://ajp.amjpathol.org). Of the 293 probe sets
corresponding to the 98 ischemia genes in both studies,
only 7 (2%) were overexpressed in BPCs compared
with BPs (q  0.05). A comparable number of ischemia
genes/probe sets were down-regulated in BPCs com-
pared with in BPs. This indicates a small and balanced
change in ischemia-related genes in BPs and BPCs.
Evidence of Cancer from the Most
Up-Regulated Markers in the Benign
Prostate Glands of Patients with PCa
We examined gene expression alterations that over-
lapped between BPCs and PCa. SNR, a metric designed
to identify genes with higher changes between two
groups than within two groups,10 was used to select
genes. BPCs and PCa were each compared with BPs,
and genes were ranked by SNR. Within the top 270 to 285
genes (350 probe sets) in the two comparisons, there
were 21 overlapping probe sets with a significant (P 
0.05) increase in BPCs and PCa compared with BPs (see
Supplemental Table S1 at http://ajp.amjpathol.org15). To
determine the significance of this overlap, we performed
1000 permutations of BP and BPC sample labels and
each time recorded the number of overlapping probe
sets using the same criteria (see Materials and Methods).
Figure 2. Permutation analysis indicates significant overlap between BPCs
and PCa in overexpressed probe sets with the highest SNRs compared with
BPs. The histogram was generated by random shuffling of BPC and BP class
labels (see Materials and Methods). The arrow points to the number of
overlapping probe sets with correct BP and BPC labels.Figure 2 is a histogram of the number of overlappingprobe sets found. The median and mean numbers of
overlapping probe sets were three and five, respectively.
Interestingly, an overlap of 21 probe sets was observed
in the top 97th percentile, indicating that expression dif-
ferences between BPs and BPCs were most likely related
to their categorization.
It is important to note that the BPCs and PCa were from
independent samples and not from matched normal tu-
mor pairs. Therefore, the significant overlaps in the top
overexpressed genes between the two categories cannot
be attributed to a common background between tumor
and adjacent benign prostate tissue samples. Also, it is
noteworthy that based on collection of the tissue and
review of the H&E slides, collection of BPC in most cases
was at a significant distance from tumor, ranging from 1
to 2 cm. However, we cannot entirely exclude the possi-
bility that some tumor may have been close to the col-
lected tissue in the three-dimensional space of the pros-
tate gland.
Expression changes in BPCs were generally smaller in
magnitude than in PCa, as shown in Figure 3 for SOX4,
CCNB1, and GPR37. The subtle but detectable expres-
sion changes were manifestations of the tumor field effect
in the benign prostate glands. From the list of up-regu-
lated candidates, seven known genes with the highest
SNRs and q  0.05 (TOP2A, DSC2, GPR37, GOLIM4,
PDGFA, SOX4, and CCNB1) were selected for validation
by RT-qPCR. We also included AMACR in the validation
experiments as previous studies indicated altered ex-
pression of AMACR by the PCa field effect.11,12
Down-Regulated Markers in BPC Include a High
Percentage of Probe Sets Containing
Nonexonic Sequences
The 50 most down-regulated probe sets in BPCs com-
pared with in BPs, based on the SNR, were selected (see
Supplemental Table S2 at http://ajp.amjpathol.org). Each
Figure 3. Expression changes compared with BPs in BPCs are smaller than
in PCa. Microarray data are depicted for three representative genes (GPR37,
SOX4, and CCNB1).
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least twofold, and this down-regulation was statistically
significant after adjusting for multiple comparisons by
false discovery rate15 (q  5  105). More than 70% of
the probe sets were also down-regulated in PCa com-
pared with in BPs (P  0.05). BLAT (BLAST-like align-
ment tool) searches in the RefSeq database revealed that
50% of the probe sets (26 of 50) had target sequences
containing misspliced or nonexonic sequences. In con-
trast, the up-regulated list (see Supplemental Table S1 at
http://ajp.amjpathol.org) contained 25% of such probe
sets. The significance of transcribed nonexonic se-
quences is currently undetermined, but they could rep-
resent long noncoding RNA important for cancer initiation
or progression20 or new gene variants. We selected five
of these probe sets that were concomitantly significantly
down-regulated in BPCs and PCa for validation by RT-
qPCR, including IDSP1 pseudogene and probe sets cor-
responding to NACA, NR2C2, PDCD5, and DLG5 loci.
RT-qPCR Confirmation and Validation of
Selected Up- and Down-Regulated Markers
in BPCs
Real-time RT-qPCR was used to confirm the findings in
the discovery step and to validate in independent sam-
ples. Confirmation used a portion of the microarray sam-
ples (see Materials and Methods). Except for PDGFA, the
average expression levels of all markers in BPC and BP
agreed with the expected trend based on the microarray
data (Table 2). GPR37, SOX4, and CCNB1 were among
Table 2. RT-qPCR Confirmation and Validation Data
Marker p-g-cnf* p-g-val* Confirmed† Trend‡
Up-regulated markers
GPR37 0.018 0.03 Yes Yes
SOX4 0.003 0.03 Yes Yes
CCNB1 0.002 0.007 Yes Yes
GOLIM4 0.173 0.052 No Yes
TOP2A 0.018 0.267 Yes Yes
AMACR 0.093 0.1 No Yes
DSC2 0.398 0.476 No Yes
PDGFA 0.255 0.716 No No
Down-regulated markers
DLG5  0.001 0.004 Yes Yes
NACA  0.001 0.003 Yes Yes
NR2C2  0.001 0.02 Yes Yes
PDCD5  0.001 0.063 Yes Yes
IDSP1  0.001 0.254 Yes Yes
Significant values are shown in bold (P  0.05). PDCD5 was marginal
(P  0.063). All but one marker (PDGFA) had the expected trend based
on the microarray data in the confirmation and validation sets.
*p-g-cnf and p-g-val are t-test P values with the null hypothesis that
expression in BPCs is not higher than that in BPs in the confirmation and
validation sets, respectively.
†Confirmed indicates whether the selected marker was significant in
the confirmation set.
‡Trend indicates whether BPC average expression was higher than
that of BP for up-regulated markers and lower than that of BP for down-
regulated markers.
§ p-ls-cnf and p-ls-val are t-test P values with the null hypothesis that
expression in BPCs is not less than that in BPs in the confirmation and
validation sets, respectively.the up-regulated genes that were confirmed and vali-dated in the independent samples (P  0.05). GOLIM4
was validated in the independent set (P  0.052), al-
though the lower expression of this gene in the confirma-
tion set was not statistically significant (P 0.173). DLG5,
NACA, and NR2C2 were confirmed and also significantly
down-regulated in independent samples, whereas
PDCD5 was marginal (P  0.063). Figure 4 is a box plot
of three up- and three down-regulated markers in BPCs
compared with BPs.
A Statistical Model Based on Two Markers
Stratified BPCs from BPs
The ability of the markers to distinguish BPCs from BPs in
the RT-qPCR data was examined by a logistic regression
that included two markers. In the confirmation and vali-
dation sets, a model that included NACA and CCNB1
produced the maximum AUC in the receiver operating
characteristic (ROC) plot (see Materials and Methods).
Figure 5A is the ROC plot in the RT-qPCR validation set
with an AUC of 0.84. The predictive ability of this model
was also examined in the public microarray data set of
Wang et al13 (GSE17951). Model coefficients were first
computed in the Mayo Clinic microarray data and then
applied to the Wang et al data set. The study by Wang et
al13 focused on the expression profiles of stroma near the
tumor, and samples were collected by macrodissection.
We identified few samples with low epithelial content
Figure 4. Box plot of six genes validated by RT-qPCR. Three up-regulated
markers (GPR37, CCNB1, and SOX4) and three down-regulated markers
(NR2C2, NACA, and DLG5) in BPCs compared with BPs are shown. The top
and bottom panels show the results of the confirmation and validation sets,
respectively. Green bars represent BP samples; red bars, BPC samples. The
horizontal line in the middle of each box indicates the median, and the top
and bottom borders of the box mark the 75th and 25th percentiles, respec-
tively. The whiskers above and below the box mark 1.5 the interquartile
range. The points beyond the whiskers are outliers beyond 1.5 the inter-
quartile range. *P  0.05, **P  0.01, and ***P  0.001.
40 Kosari et al
AJP July 2012, Vol. 181, No. 1based on prostate-specific antigen expression (see
Materials and Methods; see also Supplemental Figure S2
at http://ajp.amjpathol.org). Figure 5B is the ROC plot for
the model in the Wang et al data set after eliminating
samples with low epithelial content. This model had an
AUC of 0.90. The AUC of the model that included all the
samples, irrespective of prostate-specific antigen ex-
pression, in the Wang et al database was 0.89. These
results suggest that the field effect markers can discrim-
inate between BPs and BPCs with high accuracy.
Enriched GO Categories in BPC Stroma
Recent studies have highlighted the influence of stroma
in PCa behavior and survival.21 These studies have often
focused on reactive stroma immediately adjacent to tu-
mor. We were interested in finding whether in the microar-
ray data from bulk samples we could detect dysregulated
pathways in prostate stroma at large distances from pros-
tate tumors. We first identified genes with prominent ex-
pression in stroma by analyzing expression data from
Figure 5. A: ROC plot of the logistic regression model in the RT-qPCR
validation set. The model included NACA and CCNB1 (AUC  0.84). B: ROC
plot of the logistic regression model in the external microarray set
(GSE17951) of Wang et al13 after excluding samples with low epithelial
content (see Materials and Methods) (AUC  0.90).pure stroma and epithelial cell populations collected byLCM (see Materials and Methods). Among the identified
genes, there were 218 unique genes that were also dif-
ferentially expressed between BPCs and BPs in the bulk
microarray data. We argued that most of the differential
expression occurred in stroma as the expression levels of
these genes in stroma were on average approximately
fivefold higher than in epithelia. These genes were exam-
ined by the Matisse software package.17 The DEGAS
module in the package identified a network of 91 genes
that included 47 of 218 unique genes (22%) in our list
(see Supplemental Figure S4 at http://ajp.amjpathol.org).
Enriched GO categories in the network were examined
by the TANGO module for multiple comparison correc-
tion. Three GO categories remained significant (Table 3).
Platelet-derived growth factor (PDGF) receptor signaling
is one of the most notable carcinogenesis-related cate-
gories on the list. Also, enrichment of the “regulation of
epithelial cell differentiation” category in BPC stroma was
unexpected. Although the number of genes limited this
analysis, it was possible to identify the cancer fingerprint
in the enriched GO categories in BPC stroma.
Discussion
In this study, we observed a common cancer transcrip-
tome between histologically benign prostate tissue adja-
cent to PCa and PCa. A logistic regression model that
included down- and up-regulated markers in BPCs com-
pared with BPs predicted the presence of tumor in the
prostate gland with high accuracy in independent RT-
qPCR samples (AUC  0.84) and in an external microar-
ray data set from Wang et al13 (AUC  0.90). These
findings provide strong evidence that the transcriptome
profiles of the benign prostatic tissue can indicate the
presence or absence of PCa. We believe that using in-
dependent PCa expression profiling to guide the selec-
tion process allowed a greater likelihood of identifying
markers that would validate.
We did not observe large-scale or systematic differ-
ences in the expression profiles of BPCs and BPs. Po-
tential changes in gene expression due to ischemia were
balanced in the BP and BPC samples (Figure 1). We
expect that this partly stems from protocols followed at
the Mayo Clinic, where a unique rapid grossing, frozen
section, and tissue preservation strategy after removal of
tissue from the body is followed that significantly mini-
mizes ischemia time and reduces variation in ischemia
time. Furthermore, previous studies did not identify a
significant association between ischemia time and total
operating time with the magnitude of the gene expression
changes in ischemia.18 Therefore, even if some differ-
Table 3. GO Categories Enriched in the Network Identified by
DEGAS
Enriched GO category P value*
PDGF receptor signaling 0.028
Regulation of epithelial cell differentiation 0.017
Peptidyl-tyrosine phosphorylation 0.014*P value corrected for multiple comparisons by TANGO.
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significantly impacted the findings.
Some of the overlapping gene alterations between
BPCs and PCa are noteworthy. Cyclin B1 (CCNB1) is
essential for control of the cell cycle at the G2/M tran-
sition and, in complex with CDC2, is part of the master
mitotic regulator. Compounds such as BZL101, which
inhibit PCa growth, block CCNB1-related pathways.22
Increased expression of CCNB1 in BPCs found in the
present experiments may suggest that a small but de-
tectable group of morphologically benign prostate cells
from patients with PCa incurred compromised cell cycle
regulatory mechanisms. Sex-determining region Y-box 4
(SOX4) is involved in the regulation of embryonic devel-
opment. There is evidence that in PCa, SOX4 is involved
in the cross talk between Wnt, Notch, and PI3K path-
ways.23 The influence of GPR37 and GOLIM4 in PCa is
currently unknown. We also validated down-regulation of
nonexonic or misspliced markers that potentially code for
long (200-nucleotide) noncoding RNA or novel tran-
script variants. Recently dubbed as human cell “dark
matter” for being a major contributor to nonribosomal
RNA, long noncoding RNAs are emerging as important
contributors to tumorigenesis.20,24 Further research is re-
quired to determine whether the down-regulated markers
represent long noncoding RNA or previously unknown
transcripts and to determine their role in the initiation or
progression of PCa.
Other investigators have used expression profiling to
identify PCa field effects. Chandran et al6 used an earlier
version of the Affymetrix platform (U95A) for discovery of
gene expression changes between tumor-adjacent non-
neoplastic prostate glands and benign prostate glands
from organ donors. This study found increased expres-
sion of proliferation-related genes; however, these find-
ings were not independently validated. Haaland et al7
used a sample of six tumor and adjacent normal pairs
and six benign prostates from organ donors for profiling
on a Qiagen platform containing 37,123 transcripts. They
reported overexpression of FAS, TTP, EGR1, and
SPOCK1, but their validation set included six BPC–PCa
pairs and no independent organ donor prostate samples.
Schlomm et al25 selected 11 markers from expression
profiling and 18 markers by searching in the Oncomine
database and tested them by RT-qPCR on a set of 114
biopsy specimens from 3 risk groups. Only one of the
microarray markers (FOS) was significant. In the list of
markers selected from Oncomine, EGR1 was down-reg-
ulated and MYC, TFRC, and FOLH1 were up-regulated in
negative biopsy specimens from patients who were later
identified with PCa in a follow-up biopsy. Although this
study included a relatively large sample of clinically rel-
evant biopsies, further multi-institutional investigations
are required before these results can be applied to the
clinic. Finally, a study by Risk et al8 analyzed expression
profiles of prostate biopsies from patients with and with-
out PCa. This study was unique in profiling pure popula-
tions of epithelial cells collected by LCM. The investiga-
tors reported differential expression of ERG, HOXC4,
HOXC5, FOLH1, and MME confirmed by qPCR, two of
which (FOLH1 and MME) were also confirmed by immu-nohistochemical analysis. However, this study did not
include independent validation.
There is no high concordance between the biomarkers
identified in the aforementioned studies or with the study
presented herein for several reasons. Aside from different
detection chemistry, discrepancies in gene loci target
regions in different array platforms can be an important
contributor. For example, the down-regulated nonexonic
elements identified in this study are not featured on many
other platforms. More specific to the study of PCa field
effects is the consideration that the alterations in gene
expression in the benign prostate tissue are generally of
much lower magnitude than in PCa (Figure 3). Also, it is
often difficult to acquire a sufficient number of “normal”
samples (prostate glands without cancer), which has led
to limited statistical power and a lack of validation exper-
iments in previous studies. In the present study, we used
prostate tumor expression profiles to guide the selection
of markers that were more robust and had a reasonable
prospect for validation in independent samples. In addi-
tion, we took advantage of the relatively high number of
samples collected from cystoprostatectomy specimens
at our institution to perform discovery and validation ex-
periments.
An integrative pathway analysis by the Matisse soft-
ware package, which included gene expression values
and protein interactome data, was used to identify en-
riched GO categories in BPC stroma. Two of the three
identified categories were “PDGF receptor signaling” and
“regulation of epithelial cell differentiation.” Overexpres-
sion of PDGFs and their receptors have been reported in
many cancers, including PCa,26 and PDGF receptors are
being actively pursued as targeting agents in various
tumors.27 Also, paracrine tumor-stroma PDGF signaling
has been reported.28–30 By and large, these reports have
focused on signaling events in stroma near the tumor.
The present finding suggests that changes in the PDGF
receptor pathway are present in wide areas of peripheral
zones in prostates that harbor cancer. The additional
identification of the category “regulation of epithelial cell
differentiation” in BPC stroma is also intriguing. Whereas
epithelial to mesenchymal transition has been actively re-
searched in many solid tumors, the significance of dysregu-
lated epithelial cell differentiation signaling in prostate
stroma from patients with PCa is largely unknown. If vali-
dated in larger studies, these findings can provide impor-
tant clues regarding the initiation of prostate tumors.
Potential limitations warrant discussion. As in all stud-
ies of this nature, the presence of incidental cancers in
BP samples cannot be completely excluded. Although
the resected prostate specimens from radical cystopros-
tatectomy specimens were thoroughly analyzed grossly
and microscopically, the prostate gland was not entirely
inspected to exclude the possibility of tiny incidental can-
cer. It is also important to note that we focused these
analyses on PCa with a Gleason score 7. These tumors
are clinically most relevant and, therefore, the most im-
portant to identify in men. Also, most of the BPC samples
were from patients with tumors with Gleason scores 8.
Further work is required to determine whether insignifi-
cant cancers with a lower grade (Gleason score of 6) can
42 Kosari et al
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effect. Finally, for clinical utility, the present findings re-
quire validation in prostate needle biopsy specimens.
In conclusion, this study focused on transcriptomic
alterations that occur in morphologically benign prostate
tissue in prostate glands that harbor cancer. We con-
firmed the presence of field effect and that it occurs at
some distance from prostate tumors. Validated field ef-
fect biomarkers can be valuable in prevention trials as a
tool for choosing the correct intervention strategy or in
clinical assays aimed at identifying men who potentially
have PCa but whose prostate needle biopsy results are
negative. Larger studies are warranted before these find-
ings can be applied to clinical practice.
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